These findings indicate that the addition of sorafenib to the f‐Bu and fludarabine conditioning regimen is associated with high remission rates and favorable short‐term progression‐free survival in AML patients, including those with adverse cytogenetic profiles and FLT3 mutations. The gene discussed is FLT3; the disease is acute myeloid leukemia.